The claim 'peptides aren't safe' is not supported by the scientific literature and is, in fact, contradicted by robust human clinical trial data. Semaglutide and tirzepatide—well-characterized bioregulatory peptides—have completed Phase 2–4 RCTs demonstrating favorable risk/benefit profiles, with known, manageable side effects (primarily gastrointestinal and biliary). While peptides, like all bioactive compounds, carry context-specific risks and require appropriate sourcing and use, the categorical statement that peptides 'aren't safe' misrepresents the current state of evidence and appears designed to create blanket alarm rather than convey accurate safety information.
Share this audit
One link — full verdict, every claim, and PubMed citations included.
Shareable link includes the full verdict, claims, and PubMed citations.
Post captionshow
Who can relate 😩 #over40women #momsover40 #over40club #over40wellness
Video transcriptshow
Drink your water. Water has microplastics. Fine lines. Wrinkles. Wrinkles. Wrinkles. Retinol. Gingivitis. Get 10,000 steps. 10,000 steps hurts your feet. Joint pain. Bone loss. Peptides. Peptides aren't safe. Hair loss. Edges gone. Edges gone. Edges gone. Geriatric pregnancy. Too late to have kids. Have more kids. Hysterectomy. Hormone replacement. Get enough sleep. Can't sleep. Sleep supplement. …
Show full video transcript
Sleep supplement causes dementia. Wrinkles. Fine lines. Wrinkles. Spectra. Fillers. Cut out dairy. Cut out sugar. Oat milk gives you inflammation. Ah!
Show lessClaim breakdown
1 claim“Peptides aren't safe.”
The evidence demonstrates that peptides—specifically GLP-1 receptor agonists (semaglutide) and GIP/GLP-1 receptor agonists (tirzepatide)—have been extensively studied in human Phase 2–4 randomized controlled trials and show manageable, well-characterized safety profiles. The Smits & Van Raalte (2021) review of semaglutide (PMID: 34305810) concludes: 'No unexpected safety issues have arisen to date' and notes an 'overall favorable risk/benefit profile.' The JAMA tirzepatide trial (SURMOUNT-CN, 2024, PMID: 38819983) documents adverse events but finds the compound efficacious. Active recruitment continues in Phase 4 safety studies (NCT05702931). The blanket claim that 'peptides aren't safe' directly contradicts the established safety data for these well-studied bioregulatory peptides.
Supporting studies
- 1
Safety of Semaglutide
Frontiers in endocrinology · 2021·PMID 34305810
- 2
Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
JAMA · 2024·PMID 38819983
- 3
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials
Annals of internal medicine · 2025·PMID 39761578
- 4
Efficient amyloid-β degradation in Alzheimer's disease using SPYTACs
Cell · 2026·PMID 41785850
- 5
Long-term effect of mavacamten in obstructive hypertrophic cardiomyopathy
European heart journal · 2024·PMID 39217450
- 6
Aspartame Safety as a Food Sweetener and Related Health Hazards
Nutrients · 2023·PMID 37630817
- 7
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
International journal of clinical pharmacy · 2024·PMID 38265519
- 8
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
Drugs · 2022·PMID 35639288
This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.
Report an error